Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's

B. Tran, F. Meric-Bernstam, H. T. Arkenau, R. Bahleda, R. K. Kelley, C. Hierro, D. Ahn, A. Zhu, M. Javle, R. Winkler, H. He, J. Huang, L. Goyal

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)ix49-ix50
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Nov 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this